PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1

Condition(s) studied

Investigational drug(s) / intervention(s)

LAFOV system (an innovative, latest-generation system) scan: To collect data from the LAFOV system (an innovative, latest-generation system) during the PET scan planned as part of your treatment.

Study summary

Lung cancer is the leading cause of cancer deaths worldwide. Revolution of chemo-immunotherapy (CT-IO) in first-line of metastatic non-small-cell lung cancers (NSCLC) without actionable genomic alterations (AGAs) has dramatically improved prognosis, providing long response to a subset of patients. Because of a highly heterogeneous disease, majority of patients do not show long term benefit. Long axial field of view positron emission tomography (LAFOV-PET) scanner is a new emerging system allowing dynamic whole-body imaging with higher sensitivity, representing unique opportunity for oncological applications. The aim of this study is to determine if LAFOV-PET imaging biomarkers could early predict response to CT-IO in NSCLC.

Eligibility

Primary outcome measure(s)

• 1-year Progression-Free Survival — From date of chemo-immunotherapy initiation until the date of first documented progression or date of death, assessed up to 100 months.
  The primary endpoint is 1-year Progression-Free Survival (PFS) rate. PFS is defined as the time from chemo-immunotherapy initiation to the date of the first documented event of tumor progression or death in the absence of disease progression, whichever came first, assessed up to 100 months.

Trial sites (2)

More University Hospital, Brest trials in France

Other trials for the same condition